You just read:

MYR Pharma Announces Grant of Breakthrough Therapy Designation by US FDA for Myrcludex, the First-in-Class Entry Inhibitor for Treatment of chronic Hepatitis B and D Infections

News provided by

MYR Pharma

Oct 23, 2018, 11:46 ET